Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 7, Issue 280, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aaa3643
Keywords
-
Categories
Funding
- EU FP7 grant ATECT
- EU FP7 grant SUPERSIST
- K. G. Jebsen Center for Cancer Immunotherapy grant
- [5R01CA165206]
- [5R01CA120409]
- [5R01CA114536]
- [2R01CA136551]
Ask authors/readers for more resources
Adoptive T cell transfer for cancer, chronic infection, and autoimmunity is an emerging field that shows promise in recent trials. Using the principles of synthetic biology, advances in cell culture and genetic engineering have made it possible to generate human T cells that display desired specificities and enhanced functionalities compared with the natural immune system. The prospects for widespread availability of engineered T cells have changed dramatically, given the recent entry of the pharmaceutical industry to this arena. Here, we discuss some of the challenges-such as regulatory, cost, and manufacturing-and opportunities, including personalized gene-modified T cells, that face the field of adoptive cellular therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available